Show simple item record

dc.contributor.authorPérez García, Javier
dc.contributor.authorGonzález Carracedo, Mario
dc.contributor.authorEspuela Ortiz, Antonio
dc.contributor.authorHernández Pérez, José M.
dc.contributor.authorGonzález Pérez, Ruperto
dc.contributor.authorSardón Prado, Olaia
dc.contributor.authorMartín González, Elena
dc.contributor.authorMederos Luis, Elena
dc.contributor.authorPoza Guedes, Paloma
dc.contributor.authorCorcuera Elosegui, Paula
dc.contributor.authorCallero, Ariel
dc.contributor.authorSánchez Machín, Inmaculada
dc.contributor.authorKorta Murua, José Javier
dc.contributor.authorPérez Pérez, José Antonio
dc.contributor.authorVillar, Jesús
dc.contributor.authorPino Yanes, María
dc.contributor.authorLorenzo Díaz, Fabián
dc.date.accessioned2023-03-21T16:36:31Z
dc.date.available2023-03-21T16:36:31Z
dc.date.issued2023-03
dc.identifier.citationJournal of Allergy and Clinical Immunology 151(3) : 706-715 (2023)es_ES
dc.identifier.issn1097-6825
dc.identifier.urihttp://hdl.handle.net/10810/60433
dc.description.abstractBACKGROUND: The response to inhaled corticosteroids (ICS) in asthma is affected by the interplay of several factors. Among these, the role of the upper-airway microbiome has been scarcely investigated. We aimed to evaluate the association between the salivary, pharyngeal, and nasal microbiome with asthma exacerbations despite receipt of ICS. METHODS: Samples from 250 asthma patients from the Genomics and Metagenomics of Asthma Severity (GEMAS) study treated with ICS were analyzed. Control/case subjects were defined by the absence/presence of asthma exacerbations in the past 6 months despite being treated with ICS. The bacterial microbiota was profiled by sequencing the V3-V4 region of the 16S rRNA gene. Differences between groups were assessed by PERMANOVA and regression models adjusted for potential confounders. Afalse discovery rate (FDR) of 5% was used to correct for multiple comparisons. Classification models of asthma exacerbations despite ICS treatment were built with machine learning approaches based on clinical, genetic, and microbiome data. RESULTS: In nasal and saliva samples, case subjects had lower bacterial diversity (Richness, Shannon, and Faith indices) than control subjects (.007≤ P≤ .037). Asthma exacerbations accounted for 8% to 9% of the interindividual variation of the salivary and nasal microbiomes (.003≤ P≤ .046). Three, 4, and 11 bacterial genera from the salivary, pharyngeal, and nasal microbiomes were differentially abundant between groups (4.09*10-12≤ FDR≤ 0.047). Integrating clinical, genetic, and microbiome data showed good discrimination for the development of asthma exacerbations despite receipt of ICS (AUCtraining: 0.82 and AUCvalidation: 0.77). CONCLUSION: The diversity and composition of the upper-airway microbiome are associated with asthma exacerbations despite ICS treatment. The salivary microbiome has a potential application as a biomarker of asthma exacerbations despite receipt of ICS.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject16S rRNAes_ES
dc.subjectasthmaes_ES
dc.subjectbiomarkeres_ES
dc.subjectexacerbationses_ES
dc.subjectinhaled corticosteroidses_ES
dc.subjectmicrobiotaes_ES
dc.subjectnasales_ES
dc.subjectpharyngeales_ES
dc.subjectprecision medicinees_ES
dc.subjectsalivaes_ES
dc.titleThe upper-airway microbiome as a biomarker of asthma exacerbations despite inhaled corticosteroid treatment.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0091674922014750?via%3Dihubes_ES
dc.identifier.doi10.1016/j.jaci.2022.09.041
dc.departamentoesPediatríaes_ES
dc.departamentoeuPediatriaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Except where otherwise noted, this item's license is described as © 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)